ID Biomedical and Tm Technologies settle claims:
This article was originally published in Clinica
ID Biomedical and Tm Technologies have agreed in principle to settle their claims (see Clinica No 647, p 16). As part of the expected settlement, Tm will issue to ID Biomedical 1,330,000 shares of Tm stock and dismiss and release all litigation claims between the companies. The agreement is dependent on the approval of the Vancouver stock exchange and conditions must be satisfied by the beginning of December.
You may also be interested in...
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.
Sabinsa provided FDA and FTC with documentation of “an ingredient falsely marketed and sold as vitamin C derived from amla fruit (Emblica officinalis), which two independent labs have confirmed is actually derived from corn, sugarcane or other plants.”